IT1262896B
(it)
*
|
1992-03-06 |
1996-07-22 |
|
Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
|
JP3828145B2
(ja)
*
|
1993-09-22 |
2006-10-04 |
ヘンリー エム.ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン |
免疫原性構成物の製造のための新規シアン化試薬を使った可溶性炭水化物の活性化方法
|
US5849301A
(en)
*
|
1993-09-22 |
1998-12-15 |
Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Producing immunogenic constructs using soluable carbohydrates activated via organic cyanylating reagents
|
ATE241384T1
(de)
*
|
1995-03-22 |
2003-06-15 |
Jackson H M Found Military Med |
Herstellung von immunogenen konstrukten unter verwendung von löslichen kohlehydraten, die durch organische cyanylierungs-reagenzien aktiviert wurden
|
KR19990007858A
(ko)
*
|
1995-04-17 |
1999-01-25 |
존 더블유.로우 |
박테리아의 리포프로테인으로 폴리사카라이드에 대한 면역반응의 유도및 강화
|
US20030157129A1
(en)
*
|
1995-06-23 |
2003-08-21 |
Smithkline Beecham Biologicals S.A. |
Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein
|
US6447777B1
(en)
*
|
1996-03-29 |
2002-09-10 |
David S. Terman |
Polymerized staphylococcal protein a for treatment of diseases
|
US6309646B1
(en)
|
1996-05-09 |
2001-10-30 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Protein-polysaccharide conjugate vaccines and other immunological reagents prepared using homobifunctional and heterobifunctional vinylsulfones, and processes for preparing the conjugates
|
DE69739233D1
(de)
|
1996-06-25 |
2009-03-12 |
Pepscan Systems Bv |
Ein durch labile bindung an einen träger gebundenes antigen enthaltender impstoff
|
US6248334B1
(en)
|
1997-01-08 |
2001-06-19 |
Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Process for preparing conjugate vaccines including free protein and the conjugate vaccines, immunogens, and immunogenic reagents produced by this process
|
US6299881B1
(en)
*
|
1997-03-24 |
2001-10-09 |
Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
|
US6087328A
(en)
*
|
1997-04-24 |
2000-07-11 |
Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Coupling of unmodified proteins to haloacyl or dihaloacyl derivatized polysaccharides for the preparation of protein-polysaccharide vaccines
|
US5929049A
(en)
|
1997-08-08 |
1999-07-27 |
Dade Behring Marburg Gmbh |
Polysaccharide conjugates of biomolecules
|
ATE421339T1
(de)
*
|
1998-02-05 |
2009-02-15 |
Jackson H M Found Military Med |
Vereinfachte methode zur entfernung von freiem protein während der herstellung von protein- polysaccharid-konjugaten und impfstoffen unter verwendung von medien mit limitierter durchlässigkeit
|
WO1999047168A2
(en)
*
|
1998-03-16 |
1999-09-23 |
Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Induction and enhancement of the immune response to type-2 t cell-independent antigens conjugated to lipid or lipid-containing moieties
|
JP2002511422A
(ja)
*
|
1998-04-10 |
2002-04-16 |
リーズ,アンドリュー |
う食症予防用のコンジュゲートワクチン
|
GB9808932D0
(en)
*
|
1998-04-27 |
1998-06-24 |
Chiron Spa |
Polyepitope carrier protein
|
US6432679B1
(en)
|
1998-06-12 |
2002-08-13 |
Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Enhancement of B cell activation and immunoglobulin secretion by co-stimulation of receptors for antigen and EBV Gp350/220
|
AU767047B2
(en)
*
|
1998-07-20 |
2003-10-30 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
Vaccines against (escherichia coli) O157 infection
|
US6858211B1
(en)
*
|
1998-07-20 |
2005-02-22 |
The United States Of America As Represented By The Department Of Health And Human Services |
Vaccines against Escherichia coli O157 infection
|
US6585973B1
(en)
|
1998-10-29 |
2003-07-01 |
Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Method for preparing solid phase conjugated vaccine
|
US6797275B1
(en)
*
|
1998-12-04 |
2004-09-28 |
The United States Of America As Represented By The Department Of Health And Human Services |
Method of immunizing humans against Salmonella typhi using a Vi-rEPA conjugate vaccine
|
GB9909077D0
(en)
|
1999-04-20 |
1999-06-16 |
Smithkline Beecham Biolog |
Novel compositions
|
CZ303653B6
(cs)
|
1999-03-19 |
2013-01-30 |
Smithkline Beecham Biologicals S. A. |
Imunogenní prostredek
|
GB0108364D0
(en)
|
2001-04-03 |
2001-05-23 |
Glaxosmithkline Biolog Sa |
Vaccine composition
|
PT1296715E
(pt)
|
2000-06-29 |
2012-01-19 |
Smithkline Beecham Biolog |
Composição vacinal multivalente
|
GB0022742D0
(en)
|
2000-09-15 |
2000-11-01 |
Smithkline Beecham Biolog |
Vaccine
|
GB0115176D0
(en)
|
2001-06-20 |
2001-08-15 |
Chiron Spa |
Capular polysaccharide solubilisation and combination vaccines
|
WO2003015815A1
(en)
*
|
2001-08-21 |
2003-02-27 |
The Brigham And Women's Hospital, Inc. |
Improved conjugate vaccines
|
WO2004011027A1
(en)
*
|
2002-07-30 |
2004-02-05 |
Baxter International Inc. |
Chimeric multivalent polysaccharide conjugate vaccines
|
WO2004032958A1
(en)
|
2002-10-11 |
2004-04-22 |
Chiron Srl |
Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
|
GB0227346D0
(en)
|
2002-11-22 |
2002-12-31 |
Chiron Spa |
741
|
WO2004067030A2
(en)
|
2003-01-30 |
2004-08-12 |
Chiron Srl |
Injectable vaccines against multiple meningococcal serogroups
|
AU2004220590B2
(en)
*
|
2003-03-07 |
2010-02-18 |
Inhibitex, Inc. |
Polysaccharide - Staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
|
GB0323103D0
(en)
|
2003-10-02 |
2003-11-05 |
Chiron Srl |
De-acetylated saccharides
|
ATE506963T1
(de)
|
2003-10-02 |
2011-05-15 |
Novartis Vaccines & Diagnostic |
Kombinationsimpfstoffe gegen meningitis
|
EP1713508A2
(de)
*
|
2004-01-29 |
2006-10-25 |
Biosynexus Incorporated |
Verwendung von aminoox-funktionalen gruppen bei der herstellung von vakzine-konjugaten
|
GB0409745D0
(en)
|
2004-04-30 |
2004-06-09 |
Chiron Srl |
Compositions including unconjugated carrier proteins
|
GB0500787D0
(en)
|
2005-01-14 |
2005-02-23 |
Chiron Srl |
Integration of meningococcal conjugate vaccination
|
BRPI0510315A
(pt)
|
2004-04-30 |
2007-10-16 |
Chiron Srl |
integração de vacinação com conjugado meningocócico
|
US7456000B2
(en)
*
|
2004-08-26 |
2008-11-25 |
Siemens Healthcare Diagnostics Inc. |
Deactivation of linking moieties in antibody-enzyme conjugates
|
EP2305294B1
(de)
|
2004-09-22 |
2015-04-01 |
GlaxoSmithKline Biologicals SA |
Immunogene Zusammensetzung zur Verwendung zur Impfung gegen Staphylokokken
|
GB0505518D0
(en)
|
2005-03-17 |
2005-04-27 |
Chiron Srl |
Combination vaccines with whole cell pertussis antigen
|
CN102716480B
(zh)
|
2005-04-08 |
2023-03-21 |
惠氏有限责任公司 |
多价肺炎球菌多糖-蛋白质缀合物组合物
|
KR101408113B1
(ko)
|
2005-06-27 |
2014-06-16 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
백신 제조 방법
|
GB0524066D0
(en)
|
2005-11-25 |
2006-01-04 |
Chiron Srl |
741 ii
|
TWI457133B
(zh)
|
2005-12-13 |
2014-10-21 |
Glaxosmithkline Biolog Sa |
新穎組合物
|
CA2808919C
(en)
*
|
2005-12-22 |
2016-04-19 |
Glaxosmithkline Biologicals S.A. |
Streptococcus pneumoniae capsular saccharide vaccine
|
GB0607088D0
(en)
|
2006-04-07 |
2006-05-17 |
Glaxosmithkline Biolog Sa |
Vaccine
|
KR101411425B1
(ko)
*
|
2006-03-17 |
2014-06-24 |
더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카 에즈 레프리젠티드 바이 더 세크러테리 오브 더 디파트먼트 오브 헬스 앤드 휴먼 서비시즈 |
복합 다가 면역원성 콘쥬게이트의 제조 방법
|
NZ572054A
(en)
|
2006-03-22 |
2011-12-22 |
Novartis Ag |
Regimens for immunisation with meningococcal conjugates
|
EP2476434A1
(de)
|
2006-03-30 |
2012-07-18 |
GlaxoSmithKline Biologicals S.A. |
Immunogene Zusammensetzung
|
AU2007293673B2
(en)
|
2006-09-07 |
2013-06-27 |
Glaxosmithkline Biologicals S.A. |
Vaccine
|
US8080645B2
(en)
|
2007-10-01 |
2011-12-20 |
Longhorn Vaccines & Diagnostics Llc |
Biological specimen collection/transport compositions and methods
|
US9481912B2
(en)
|
2006-09-12 |
2016-11-01 |
Longhorn Vaccines And Diagnostics, Llc |
Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
|
US8097419B2
(en)
|
2006-09-12 |
2012-01-17 |
Longhorn Vaccines & Diagnostics Llc |
Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
|
GB0700136D0
(en)
|
2007-01-04 |
2007-02-14 |
Glaxosmithkline Biolog Sa |
Process for manufacturing vaccines
|
EP2142211A1
(de)
|
2007-05-02 |
2010-01-13 |
GlaxoSmithKline Biologicals S.A. |
Impfstoff
|
EP2687228B1
(de)
|
2007-06-26 |
2017-07-19 |
GlaxoSmithKline Biologicals S.A. |
Impfstoff mit streptococcus pneumoniae-kapsulären polysaccharid-konjugaten
|
GB0713880D0
(en)
|
2007-07-17 |
2007-08-29 |
Novartis Ag |
Conjugate purification
|
US11041215B2
(en)
|
2007-08-24 |
2021-06-22 |
Longhorn Vaccines And Diagnostics, Llc |
PCR ready compositions and methods for detecting and identifying nucleic acid sequences
|
CA2697373C
(en)
|
2007-08-27 |
2019-05-21 |
Longhorn Vaccines & Diagnostics, Llc |
Immunogenic compositions and methods
|
US10004799B2
(en)
|
2007-08-27 |
2018-06-26 |
Longhorn Vaccines And Diagnostics, Llc |
Composite antigenic sequences and vaccines
|
GB0818453D0
(en)
|
2008-10-08 |
2008-11-12 |
Novartis Ag |
Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
|
NZ587382A
(en)
|
2008-02-21 |
2012-01-12 |
Novartis Ag |
Meningococcal fhbp polypeptides
|
WO2010042481A1
(en)
|
2008-10-06 |
2010-04-15 |
University Of Chicago |
Compositions and methods related to bacterial eap, emp, and/or adsa proteins
|
GB0822634D0
(en)
|
2008-12-11 |
2009-01-21 |
Novartis Ag |
Meningitis vaccines
|
GB0822633D0
(en)
|
2008-12-11 |
2009-01-21 |
Novartis Ag |
Formulation
|
KR20170102039A
(ko)
|
2009-04-03 |
2017-09-06 |
유니버시티 오브 시카고 |
단백질 A(SpA) 변이체와 관련된 조성물 및 방법
|
WO2010135714A2
(en)
|
2009-05-22 |
2010-11-25 |
The Methodist Hospital Research Institute |
Methods for modulating adipocyte expression using microrna compositions
|
WO2010141312A2
(en)
|
2009-06-01 |
2010-12-09 |
Wake Forest University Health Sciences |
Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same
|
WO2010151544A1
(en)
|
2009-06-22 |
2010-12-29 |
Wyeth Llc |
Immunogenic compositions of staphylococcus aureus antigens
|
JP2012530785A
(ja)
|
2009-06-22 |
2012-12-06 |
ワイス・エルエルシー |
組成物および黄色ブドウ球菌(Staphylococcusaureus)血清型5および8莢膜多糖コンジュゲート免疫原性組成物を調製するための方法
|
WO2011017101A2
(en)
|
2009-07-27 |
2011-02-10 |
Fina Biosolutions, Llc |
Method for producing protein-carbohydrate vaccines reduced in free carbohydrate
|
GB0913680D0
(en)
|
2009-08-05 |
2009-09-16 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
GB0913681D0
(en)
|
2009-08-05 |
2009-09-16 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
WO2011024072A2
(en)
|
2009-08-27 |
2011-03-03 |
Novartis Ag |
Hybrid polypeptides including meningococcal fhbp sequences
|
WO2011036560A2
(en)
|
2009-09-23 |
2011-03-31 |
Novartis Ag |
Glycoconjugate compositions and methods for treatment of hiv
|
AU2010302344A1
(en)
|
2009-09-30 |
2012-04-26 |
Novartis Ag |
Expression of meningococcal fhbp polypeptides
|
GB0917647D0
(en)
|
2009-10-08 |
2009-11-25 |
Glaxosmithkline Biolog Sa |
Expression system
|
BR112012010531A2
(pt)
|
2009-10-27 |
2019-09-24 |
Novartis Ag |
"polipeptídeos de modificação meningocócica fhbp"
|
WO2011084705A2
(en)
|
2009-12-17 |
2011-07-14 |
Fina Biosolutions, Llc |
Chemical reagents for the activation of polysaccharides in the preparation of conjugate vaccines
|
GB201003922D0
(en)
|
2010-03-09 |
2010-04-21 |
Glaxosmithkline Biolog Sa |
Conjugation process
|
GB201003924D0
(en)
|
2010-03-09 |
2010-04-21 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
US8808699B2
(en)
|
2010-04-05 |
2014-08-19 |
The University Of Chicago |
Compositions and methods related to protein A (SpA) antibodies as an enhancer of immune response
|
NZ602971A
(en)
|
2010-04-23 |
2014-11-28 |
Serum Inst India Ltd |
Simple method for simultaneous removal of multiple impurities from culture supernatants to ultralow levels
|
AU2011274367B2
(en)
|
2010-07-02 |
2015-04-23 |
The University Of Chicago |
Compositions and methods related to protein A (SpA) variants
|
WO2012034067A1
(en)
|
2010-09-09 |
2012-03-15 |
The University Of Chicago |
Methods and compositions involving protective staphylococcal antigens
|
GB201106225D0
(en)
|
2011-04-13 |
2011-05-25 |
Glaxosmithkline Biolog Sa |
Fermentation process
|
US8945588B2
(en)
|
2011-05-06 |
2015-02-03 |
The University Of Chicago |
Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
|
AU2012335208B2
(en)
|
2011-11-07 |
2017-08-31 |
Glaxosmithkline Biologicals S.A. |
Carrier molecule comprising a spr0096 and a spr2021 antigen
|
GB201121301D0
(en)
|
2011-12-12 |
2012-01-25 |
Novartis Ag |
Method
|
SA115360586B1
(ar)
|
2012-03-09 |
2017-04-12 |
فايزر انك |
تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
|
NZ702285A
(en)
|
2012-04-26 |
2016-07-29 |
Univ Chicago |
Staphylococcal coagulase antigens and methods of their use
|
BR112015008040A2
(pt)
|
2012-10-12 |
2017-07-04 |
Glaxosmithkline Biologicals Sa |
composição de vacina, vacina de combinação, e, processos para preparar um componente ap e para a fabricação de uma composição de vacina
|
WO2014102265A1
(en)
|
2012-12-27 |
2014-07-03 |
Glycovaxyn Ag |
Methods and compositions relating to crm197
|
DK2863943T3
(en)
|
2013-03-08 |
2016-11-07 |
Janssen Vaccines & Prevention Bv |
acellular pertussis vaccines
|
GB201310008D0
(en)
|
2013-06-05 |
2013-07-17 |
Glaxosmithkline Biolog Sa |
Immunogenic composition for use in therapy
|
CA2923129C
(en)
|
2013-09-08 |
2020-06-09 |
Pfizer Inc. |
Neisseria meningitidis compositions and methods thereof
|
MY194920A
(en)
*
|
2013-10-11 |
2022-12-23 |
Msd Wellcome Trust Hilleman Laboratories Pvt Ltd |
Polysaccharide ? protein conjugates with enhanced immunogenicity and rapid high yielding process thereof
|
US11708411B2
(en)
|
2013-12-20 |
2023-07-25 |
Wake Forest University Health Sciences |
Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
|
PL3583947T3
(pl)
|
2014-01-21 |
2024-04-02 |
Pfizer Inc. |
Polisacharydy otoczkowe streptococcus pneumoniae i ich koniugaty
|
US11160855B2
(en)
|
2014-01-21 |
2021-11-02 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
PL3096785T3
(pl)
|
2014-01-21 |
2021-03-08 |
Pfizer Inc. |
Kompozycje immunogenne zawierające skoniugowane antygeny sacharydów otoczkowych i ich zastosowania
|
DK3099800T3
(da)
|
2014-01-31 |
2021-01-11 |
Fina Biosolutions Llc |
Ekspression og oprensning af crm197 og beslægtede proteiner
|
BR112016019735A2
(pt)
|
2014-02-28 |
2017-10-17 |
Glaxosmithkline Biologicals Sa |
fhbp, polipeptídeo, plasmídeo ou outro ácido nucleico, célula hospedeira, vesículas de membrana, e, composição imunogênica
|
EP2921856B1
(de)
|
2014-03-18 |
2016-09-14 |
Serum Institute Of India Private Limited |
Quantitativer test für 4-pyrrolidinopyridin (4-ppy) in konjugatimpfstoffen aus polysaccharid-protein
|
US9815886B2
(en)
|
2014-10-28 |
2017-11-14 |
Adma Biologics, Inc. |
Compositions and methods for the treatment of immunodeficiency
|
EP3229833A1
(de)
|
2014-12-10 |
2017-10-18 |
GlaxoSmithKline Biologicals SA |
Behandlungsverfahren
|
EP3034516A1
(de)
|
2014-12-19 |
2016-06-22 |
Novartis AG |
Reinigung von Streptokokkenkapselpolysaccharid
|
EP3244917B1
(de)
|
2015-01-15 |
2023-04-19 |
Pfizer Inc. |
Immunogene zusammensetzungen zur verwendung in pneumokokkenimpfstoffen
|
JP2018511655A
(ja)
|
2015-03-20 |
2018-04-26 |
ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン |
ボルデテラ属に対するワクチン接種における使用のための免疫原性組成物
|
IL297740A
(en)
|
2015-05-04 |
2022-12-01 |
Pfizer |
Protein-polysaccharide conjugates of group b streptococcus, methods for preparing the conjugates, immunogenic preparations containing conjugates and their uses
|
DK3313436T3
(da)
|
2015-06-23 |
2021-03-08 |
Biological E Ltd |
Multivalent pneumokok-konjugatvaccine
|
MY192183A
(en)
|
2015-07-21 |
2022-08-05 |
Pfizer |
Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
|
GB201518684D0
(en)
|
2015-10-21 |
2015-12-02 |
Glaxosmithkline Biolog Sa |
Vaccine
|
JP6884145B2
(ja)
|
2015-11-20 |
2021-06-09 |
ファイザー・インク |
肺炎連鎖球菌ワクチンにおいて用いるための免疫原性組成物
|
GB201610599D0
(en)
|
2016-06-17 |
2016-08-03 |
Glaxosmithkline Biologicals Sa |
Immunogenic Composition
|
EP3474890A1
(de)
|
2016-06-22 |
2019-05-01 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften E. V. |
Pneumokokken-polysaccharid-proteinkonjugat-zusammensetzung
|
EP3269385A1
(de)
|
2016-07-12 |
2018-01-17 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Pneumokokken-polysaccharid-proteinkonjugatzusammensetzung
|
AU2017306708B2
(en)
|
2016-08-05 |
2021-08-26 |
Sk Bioscience Co., Ltd. |
Multivalent pneumococcal polysaccharide-protein conjugate composition
|
SG11201900794PA
(en)
|
2016-08-05 |
2019-02-27 |
Sanofi Pasteur Inc |
Multivalent pneumococcal polysaccharide-protein conjugate composition
|
JP7104027B2
(ja)
|
2016-09-02 |
2022-07-20 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
淋菌に対するワクチン
|
KR101991457B1
(ko)
*
|
2016-09-06 |
2019-09-30 |
주식회사 엘지화학 |
다가 협막 다당류-운반 단백질을 포함하는 조성물 및 이의 용도
|
EP3518965A1
(de)
|
2016-09-30 |
2019-08-07 |
Biological E Limited |
Mehrwertige pneumokokken-impfstoffzusammensetzungen mit polysaccharidproteinkonjugaten
|
US10751402B2
(en)
|
2016-11-09 |
2020-08-25 |
Pfizer Inc. |
Immunogenic compositions and uses thereof
|
US20210108002A1
(en)
|
2016-12-06 |
2021-04-15 |
Glaxosmithkline Biologicals Sa |
Purification Process For Capsular Polysaccharide
|
CN110198735A
(zh)
|
2017-01-20 |
2019-09-03 |
辉瑞公司 |
用于肺炎球菌疫苗中的免疫原性组合物
|
US20200222550A1
(en)
|
2017-01-31 |
2020-07-16 |
Merck Sharp & Dohme Corp. |
Methods for production of capsular polysaccharide protein conjugates from streptococcus pneumoniae serotype 19f
|
CN110234658B
(zh)
|
2017-01-31 |
2024-03-12 |
辉瑞大药厂 |
脑膜炎奈瑟菌组合物及其使用方法
|
US10259865B2
(en)
|
2017-03-15 |
2019-04-16 |
Adma Biologics, Inc. |
Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
|
CN111093650B
(zh)
|
2017-09-07 |
2024-03-01 |
默沙东有限责任公司 |
肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途
|
GEP20227420B
(en)
|
2017-12-06 |
2022-10-10 |
Merck Sharp & Dohme Llc |
Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
|
GB201721576D0
(en)
|
2017-12-21 |
2018-02-07 |
Glaxosmithkline Biologicals Sa |
Hla antigens and glycoconjugates thereof
|
GB201721582D0
(en)
|
2017-12-21 |
2018-02-07 |
Glaxosmithkline Biologicals Sa |
S aureus antigens and immunogenic compositions
|
JP7446279B2
(ja)
|
2018-07-19 |
2024-03-08 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
乾燥多糖を調製するための方法
|
EP3607967A1
(de)
|
2018-08-09 |
2020-02-12 |
GlaxoSmithKline Biologicals S.A. |
Modifizierte meningokokken fhbp polypeptide
|
JP2022513458A
(ja)
|
2018-12-12 |
2022-02-08 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
O-結合型グリコシル化のための修飾キャリアタンパク質
|
JP2022512345A
(ja)
|
2018-12-12 |
2022-02-03 |
ファイザー・インク |
免疫原性多重ヘテロ抗原多糖-タンパク質コンジュゲートおよびその使用
|
JOP20210148A1
(ar)
|
2018-12-19 |
2023-01-30 |
Merck Sharp & Dohme |
تركيبات تشتمل على متقارنات بولي سكاريد-بروتين للمكورات العقدية الرئوية وطرق استخدامها
|
WO2020165711A1
(en)
|
2019-02-11 |
2020-08-20 |
Pfizer Inc. |
Neisseria meningitidiscompositions and methods thereof
|
JP7239509B6
(ja)
|
2019-02-22 |
2023-03-28 |
ファイザー・インク |
細菌多糖類を精製するための方法
|
CA3136278A1
(en)
|
2019-04-10 |
2020-10-15 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
|
CA3139257A1
(en)
|
2019-05-10 |
2020-11-19 |
Glaxosmithkline Biologicals Sa |
Conjugate production
|
EP3757217A1
(de)
|
2019-06-27 |
2020-12-30 |
GlaxoSmithKline Biologicals S.A. |
Verfahren zur proteinaufreinigung
|
KR20220042378A
(ko)
|
2019-07-31 |
2022-04-05 |
사노피 파스퇴르 인코포레이티드 |
다가 폐렴구균 다당류-단백질 접합체 조성물 및 그 사용 방법
|
EP3777884A1
(de)
|
2019-08-15 |
2021-02-17 |
GlaxoSmithKline Biologicals S.A. |
Immunogene zusammensetzung
|
EP4034157A1
(de)
|
2019-09-27 |
2022-08-03 |
Pfizer Inc. |
Neisseria-meningitidis-zusammensetzungen und verfahren dafür
|
EP3799884A1
(de)
|
2019-10-01 |
2021-04-07 |
GlaxoSmithKline Biologicals S.A. |
Immunogene zusammensetzungen
|
CA3161857A1
(en)
|
2019-11-22 |
2021-05-27 |
Glaxosmithkline Biologicals Sa |
Dosage and administration of a bacterial saccharide glycoconjugate vaccine
|
CA3171864A1
(en)
|
2020-02-21 |
2021-08-26 |
Pfizer Inc. |
Purification of saccharides
|
WO2021176409A1
(en)
|
2020-03-05 |
2021-09-10 |
Sanofi Healthcare India Private Limited |
Preservative combination for vaccine composition
|
EP3900739A1
(de)
|
2020-04-21 |
2021-10-27 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Synthetische streptococcus-pneumoniae-saccharid-konjugate zum konservierten membranprotein
|
EP3919076A1
(de)
|
2020-06-02 |
2021-12-08 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Synthetische oligosaccharidimpfstoffe gegen streptococcus pneumoniae mit mikropartikel-adjuvans-formulierungen
|
JP2023529925A
(ja)
|
2020-06-12 |
2023-07-12 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
ナノ粒子ワクチンを使用する細菌免疫化
|
JP2023531059A
(ja)
|
2020-06-25 |
2023-07-20 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
肺炎桿菌o抗原ワクチン
|
GB202013262D0
(en)
|
2020-08-25 |
2020-10-07 |
Glaxosmithkline Biologicals Sa |
Vaccine Composition
|
EP4203995A1
(de)
|
2020-08-26 |
2023-07-05 |
Pfizer Inc. |
Gruppe-b-streptococcus-polysaccharid-protein-konjugate, verfahren zur herstellung von konjugaten, immunogene zusammensetzungen mit konjugaten und verwendungen davon
|
IL301248B2
(en)
|
2020-09-17 |
2024-04-01 |
Janssen Pharmaceuticals Inc |
Multivalent vaccine compositions and their uses
|
CA3196222A1
(en)
|
2020-10-20 |
2022-04-28 |
Xianchao ZHU |
Proteoglycan conjugate and application thereof
|
EP4232593A1
(de)
|
2020-10-22 |
2023-08-30 |
Pfizer Inc. |
Verfahren zur reinigung von bakteriellen polysacchariden
|
KR20230097160A
(ko)
|
2020-11-04 |
2023-06-30 |
화이자 인코포레이티드 |
폐렴구균 백신에 사용하기 위한 면역원성 조성물
|
WO2023111826A1
(en)
|
2021-12-14 |
2023-06-22 |
Glaxosmithkline Biologicals Sa |
Bacterial immunization using qbeta hairpin nanoparticle constructs
|
WO2023118033A1
(en)
|
2021-12-22 |
2023-06-29 |
Glaxosmithkline Biologicals Sa |
Vaccine
|
GB202208089D0
(en)
|
2022-06-01 |
2022-07-13 |
Glaxosmithkline Biologicals Sa |
Immunogenic composition
|
CN114965784B
(zh)
*
|
2022-06-01 |
2023-10-27 |
艾美探索者生命科学研发有限公司 |
多糖活化度的测定方法
|
GB202208093D0
(en)
|
2022-06-01 |
2022-07-13 |
Glaxosmithkline Biologicals Sa |
Immunogenic composition
|
WO2024110839A2
(en)
|
2022-11-22 |
2024-05-30 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2024116096A1
(en)
|
2022-12-01 |
2024-06-06 |
Pfizer Inc. |
Pneumococcal conjugate vaccine formulations
|